Janssen Ups Influenza Investment with US$780 M Bet on Cidara’s AVC Platform
By Michelle Liu
Pharma Deals Review: Vol 2021 Issue 4 (Table of Contents)
Published: 21 Apr-2021
DOI: 10.3833/pdr.v2021.i4.2608 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Janssen Pharmaceuticals has entered into a worldwide license and collaboration agreement with Cidara Therapeutics to develop antiviral conjugates (AVCs) for the prevention and treatment of influenza...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS